Sun Pharma acquires three brands to boost anti-inflammatory portfolio | Mint
Active Stocks
Mon Feb 26 2024 11:18:14
  1. Tata Steel share price
  2. 144.15 -0.93%
  1. Power Grid Corporation Of India share price
  2. 288.85 2.36%
  1. ITC share price
  2. 409.70 -0.46%
  1. State Bank Of India share price
  2. 756.60 -0.37%
  1. HDFC Bank share price
  2. 1,425.90 0.35%
Business News/ Companies / News/  Sun Pharma acquires three brands to boost anti-inflammatory portfolio
BackBack

Sun Pharma acquires three brands to boost anti-inflammatory portfolio

Sun Pharma has acquired three brands--Disperzyme, Disperzyme-CD, and Phlogam from Aksigen Hospital Care

Sun Pharma says there is great asymmetry in the information circulating between analysts, investors and media, leading to intense speculation. Photo: MintPremium
Sun Pharma says there is great asymmetry in the information circulating between analysts, investors and media, leading to intense speculation. Photo: Mint

Pharmaceutical major Sun Pharma on Monday announced that it has acquired three brands--Disperzyme, Disperzyme-CD, and Phlogam from Aksigen Hospital Care.

In a BSE stock filing, Sun Pharma informed that Aksigen is a Mumbai-based research-driven healthcare entity with more than two decades of experience in the healthcare field.

Disperzyme and Phlogam are the first enzyme-bioflavonoid combination of Trypsin, Bromelain, and Rutoside (“TBR") to complete a clinical study in India and get DCGI approval. The brands were registered and launched in India by Aksigen in 2013, Sun Pharma said in a press statement.

“The addition of Disperzyme and Phlogam further strengthens our anti-inflammatory portfolio. This systemic enzyme therapy combination is being used to control edema and it speeds up the healing process. In a comparative clinical trial in India, the brands provided significantly better control and resolution of postoperative pain and inflammation," Kirti Ganorkar, CEO-India business, Sun Pharma.

The overall market of proteolytic enzymes for healing, pain, and edema in India is around 500 crore.

Last week Sun Pharmaceutical Industries launched its phenobarbital sodium injection, SEZABY for the treatment of neonatal seizures in the US.

SEZABY is the first and only product approved by the USFDA for the treatment of neonatal seizures in term and preterm infants, the company said.

Sun Pharma SEZABY was granted 'orphan drug' designation by the USFDA for the treatment of neonatal seizures.

Orphan drug designation is granted by the USFDA to a medicine intended to treat a condition affecting fewer than 2 lakh persons in the US, or which will not be profitable within seven years following its approval.

Shares of Sun Pharma were up at 0.33% at 1 pm on Monday.

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

Catch all the Corporate news and Updates on Live Mint. Check all the latest action on Budget 2024 here. Download The Mint News App to get Daily Market Updates & Live Business News.
More Less
Published: 30 Jan 2023, 01:05 PM IST
Next Story footLogo
Recommended For You
Switch to the Mint app for fast and personalized news - Get App